Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer.

Link:
Autor/in:
Erscheinungsjahr:
2010
Medientyp:
Text
Schlagworte:
  • Humans
  • Male
  • Aged
  • Middle Aged
  • Prostate-Specific Antigen blood
  • Immunohistochemistry
  • Prognosis
  • Up-Regulation
  • Neoplasm Recurrence, Local genetics
  • Gene Amplification
  • In Situ Hybridization, Fluorescence
  • Prostatic Neoplasms genetics
  • Receptor, erbB-2 biosynthesis
  • Tissue Array Analysis
  • Tumor Markers, Biological analysis
  • Humans
  • Male
  • Aged
  • Middle Aged
  • Prostate-Specific Antigen blood
  • Immunohistochemistry
  • Prognosis
  • Up-Regulation
  • Neoplasm Recurrence, Local genetics
  • Gene Amplification
  • In Situ Hybridization, Fluorescence
  • Prostatic Neoplasms genetics
  • Receptor, erbB-2 biosynthesis
  • Tissue Array Analysis
  • Tumor Markers, Biological analysis
Beschreibung:
  • The HER2 oncogene is involved in the biology of many different tumor types and serves as a prognostic marker and a therapeutic target in breast cancer. In contrast to breast cancer, studies on Her2 overexpression and gene amplification in prostate cancer have yielded different results. The purpose of this study was to learn more on the prevalence and clinical significance of HER2 amplification and overexpression in prostate cancer.
  • The HER2 oncogene is involved in the biology of many different tumor types and serves as a prognostic marker and a therapeutic target in breast cancer. In contrast to breast cancer, studies on Her2 overexpression and gene amplification in prostate cancer have yielded different results. The purpose of this study was to learn more on the prevalence and clinical significance of HER2 amplification and overexpression in prostate cancer.
Lizenz:
  • info:eu-repo/semantics/restrictedAccess
Quellsystem:
Forschungsinformationssystem des UKE

Interne Metadaten
Quelldatensatz
oai:pure.atira.dk:publications/90a18294-7893-4deb-8237-0300b7a4bb11